<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe a patient with <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (APL) who was successfully induced into remission with <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) and <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, but developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 shortly after conclusion of maintenance therapy with <z:chebi fb="0" ids="42068">idarubicin</z:chebi> alternating with <z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients on combination regimens of ATRA or other <z:chebi fb="0" ids="26537">retinoids</z:chebi> and chemotherapy, which are being increasingly used in recent years, should be closely monitored for the development of potentially new complications including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>